<?xml version="1.0" encoding="UTF-8"?>
<results title="zoonosis">
 <result pre="coronavirus epidemics such as the 2003 SARS-CoV and the 2012" exact="Middle East respiratory syndrome" post="coronavirus (MERS-CoV) prompted the identification of compounds that could"/>
 <result pre="in previous viral pandemics, including Spanish flu in 1918 and" exact="Middle East respiratory syndrome" post="coronavirus (MERS-CoV) in 2012, and this is also the"/>
 <result pre="appeared in the market with strong claims of effectiveness against" exact="SARS-CoV-2 infection." post="Some constitute a risk on patientsâ€™ health, e.g., chlorine"/>
 <result pre="Uncontrolled pulmonary inflammation is a major cause of death in" exact="SARS-CoV-2 infection." post="More than 80% of patients with COVID-19 have lymphopenia"/>
 <result pre="Agents Several approaches have been suggested to target the current" exact="SARS-CoV-2 infection" post="in moderate-to-severe cases in an attempt to control viral"/>
 <result pre="is an inhibitor of translation elongationâ€&quot;as potential effective therapies for" exact="SARS-CoV-2 infection." post="The study is under review [14]. 3.1.1. Remdesivir (GS-5734)"/>
 <result pre="chains. The drug was first developed for the treatment of" exact="Ebola" post="infection [15,16]. It was found to be a promising"/>
 <result pre="Institute. Umifenovir is approved for the prophylaxis and treatment of" exact="human influenza" post="type A and type B infections, as well as"/>
 <result pre="leading to apoptosis [45]. Similar to a previous study on" exact="SARS-CoV infection," post="it can be speculated that viroporin 3a may activate"/>
 <result pre="protein 3 (NLRP3) and inflammasome, thus inducing cell pyroptosis in" exact="SARS-CoV-2 infection" post="[46]. Tranilast is an antagonist of NLRP3 that inhibits"/>
 <result pre="the decrease in viral load), anti-spike protein-neutralizing antibodies (anti-S-IgG) in" exact="SARS-CoV infection" post="have been found to cause severe lung injury by"/>
 <result pre="[103], dengue virus (DENV), [104], West Nile virus (WNV) infection," exact="Japanese encephalitis" post="virus (JEV), and Zika virus infection [105]. Those specific"/>
 <result pre="to inhibit other flavivirus replication, including: dengue, tick-borne encephalitis, and" exact="Japanese encephalitis" post="viruses. One of the mechanisms involved in this inhibition"/>
 <result pre="syncytial virus, and influenza virus [118,119]. In addition, Zika and" exact="Ebola" post="viruses have been shown to be inhibited by azithromycin"/>
 <result pre="and ARB via increasing the ACE2 levels and opposing the" exact="SARS-CoV-2 infection" post="consequences. Losartan is an AT1R blocker that is widely"/>
 <result pre="A small clinical trial of rhACE2 in patients with severe" exact="SARS-CoV-2 infection" post="was recently initiated (NCT04287686). Logically, low cellular membrane ACE2"/>
 <result pre="effects of ACE2 and, hence, ACEi/ARB or rhACE2, treatment in" exact="SARS-CoV-2 infection" post="need more investigation. 6.2. Camostat In-vitro studies have shown"/>
 <result pre="drugs presented in this review are possible pharmacological modalities to" exact="COVID 19," post="but most of them are proposed based on their"/>
 <result pre="target virus entry, replication, and associated complications. The management of" exact="COVID 19" post="is rapidly evolving, as all available therapies are currently"/>
 <result pre="specificity of the papain-like protease domain of nsp3 from the" exact="Middle East respiratory syndrome" post="coronavirusJ. Virol.201488125111252710.1128/JVI.01294-1425142582 10.TsengY.-T.WangS.-M.HuangK.-J.LeeA.I.-R.ChiangC.-C.WangC.-T.Self-assembly of severe acute respiratory syndrome coronavirus"/>
 <result pre="Commun.20189401310.1038/s41467-018-06215-z30275474 17.WarrenT.K.JordanR.LoM.K.RayA.S.MackmanR.L.SolovevaV.SiegelD.PerronM.BannisterR.HuiH.C.et al.Therapeutic efficacy of the small molecule GS-5734 against" exact="Ebola" post="virus in rhesus monkeysNature201653138138510.1038/nature1718026934220 18.GordonC.J.TchesnokovE.P.FengJ.Y.PorterD.P.GotteM.The antiviral compound remdesivir potently"/>
 <result pre="18.GordonC.J.TchesnokovE.P.FengJ.Y.PorterD.P.GotteM.The antiviral compound remdesivir potently inhibits RNA-dependent RNA polymerase from" exact="Middle East respiratory syndrome" post="coronavirusJ. Biol. Chem.20202954772477910.1074/jbc.AC120.013056 19.De WitE.FeldmannF.CroninJ.JordanR.OkumuraA.ThomasT.ScottD.CihlarT.FeldmannH.Prophylactic and therapeutic remdesivir (GS-5734)"/>
 <result pre="findingsThorax20045925225610.1136/thorax.2003.01265814985565 34.Al-TawfiqJ.A.MomattinH.DibJ.MemishZ.A.Ribavirin and interferon therapy in patients infected with the" exact="Middle East respiratory syndrome" post="coronavirus: An observational studyInt. J. Infect. Dis.201420424610.1016/j.ijid.2013.12.00324406736 35.OmraniA.S.SaadM.M.BaigK.BahloulA.Abdul-MatinM.AlaidaroosA.Y.AlmakhlafiG.A.AlbarrakM.M.MemishZ.A.AlbarrakA.M.Ribavirin and"/>
 <result pre="studyInt. J. Infect. Dis.201420424610.1016/j.ijid.2013.12.00324406736 35.OmraniA.S.SaadM.M.BaigK.BahloulA.Abdul-MatinM.AlaidaroosA.Y.AlmakhlafiG.A.AlbarrakM.M.MemishZ.A.AlbarrakA.M.Ribavirin and interferon alfa-2a for severe" exact="Middle East respiratory syndrome" post="coronavirus infection: A retrospective cohort studyLancet Infect. Dis.2014141090109510.1016/S1473-3099(14)70920-X25278221 36.SpanakisN.TsiodrasS.HaagmansB.L.RajV.S.PontikisK.KoutsoukouA.KoulourisN.G.OsterhausA.D.M.E.KoopmansM.P.G.TsakrisA.Virological"/>
 <result pre="studyLancet Infect. Dis.2014141090109510.1016/S1473-3099(14)70920-X25278221 36.SpanakisN.TsiodrasS.HaagmansB.L.RajV.S.PontikisK.KoutsoukouA.KoulourisN.G.OsterhausA.D.M.E.KoopmansM.P.G.TsakrisA.Virological and serological analysis of a recent" exact="Middle East respiratory syndrome" post="coronavirus infection case on a triple combination antiviral regimenInt."/>
 <result pre="of anti-inflammatory drugs in the treatment of people with severe" exact="coronavirus disease 2019" post="(COVID-19): The perspectives of clinical immunologists from ChinaClin. Immunol.202021410839310.1016/j.clim.2020.10839332222466"/>
 <result pre="of clinical immunologists from ChinaClin. Immunol.202021410839310.1016/j.clim.2020.10839332222466 62.DongL.HuS.GaoJ.Discovering drugs to treat" exact="coronavirus disease 2019" post="(COVID-19)Drug Discov. Ther.202014586010.5582/ddt.2020.0101232147628 63.CostantiniC.BelletM.M.ParianoM.RengaG.StincardiniC.GoldsteinA.L.GaraciE.RomaniL.A reappraisal of thymosin Alpha1 in"/>
 <result pre="infectivity by chloroquineAIDS Res. Hum. Retroviruses1990648148910.1089/aid.1990.6.4811692728 103.OoiE.E.ChewJ.S.LohJ.P.ChuaR.C.In vitro inhibition of" exact="human influenza" post="a virus replication by chloroquineVirol. J.200633910.1186/1743-422X-3-3916729896 104.FariasK.J.MachadoP.R.Da FonsecaB.A.Chloroquine inhibits"/>
 <result pre="by interfering with virus internalization processJ. Antibiot.20197275976810.1038/s41429-019-0204-x31300721 120.MadridP.B.PanchalR.G.WarrenT.K.ShurtleffA.C.EndsleyA.N.GreenC.E.KolokoltsovA.DaveyR.MangerI.D.GilfillanL.et al.Evaluation of" exact="Ebola" post="virus inhibitors for drug repurposingACS Infect. Dis.2015131732610.1021/acsinfecdis.5b0003027622822 121.IannettaM.IppolitoG.NicastriE.Azithromycin shows"/>
 <result pre="in the upper right. Figure 2 Inflammatory responses triggered by" exact="SARS-CoV-2 infection." post="Two inflammatory pathways may be distinguished. The primary pathway"/>
</results>
